{
    "clinical_study": {
        "@rank": "134324", 
        "arm_group": {
            "arm_group_label": "ACH-0143102 plus ribavirin", 
            "arm_group_type": "Experimental", 
            "description": "ACH-0143102 225 mg loading dose on Day 1 followed by 75 mg maintenance dose for 12 weeks plus RBV either 1000mg if weight <75 kg or 1200 mg if weight > 75 kg."
        }, 
        "brief_summary": {
            "textblock": "ACH-0143102 plus ribavirin will lower viral load in hepatitis C genotype 1b treatment naive\n      subjects."
        }, 
        "brief_title": "Evaluation of Safety Tolerability and Antiviral Activity of ACH-0143102 Plus RBV Treatment Naive HCV GT1b Subjects", 
        "completion_date": {
            "#text": "September 2013", 
            "@type": "Actual"
        }, 
        "condition": "Chronic Hepatitis C Infection", 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis, Chronic", 
                "Hepatitis C", 
                "Hepatitis C, Chronic"
            ]
        }, 
        "detailed_description": {
            "textblock": "A phase 1b, pilot study to evaluate the safety, tolerability and antiviral activity of oral\n      ACH-0143102 administered in combination with ribavirin for 12 weeks in treatment naive\n      subjects with chronic hepatitis C virus infection genotype 1b."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Clinical diagnosis of Hepatitis C with genotype 1b\n\n          -  Chronic hepatitis C treatment naive subjects\n\n        Exclusion Criteria:\n\n          -  BMI>36\n\n          -  pregnant or nursing females\n\n          -  clinically significant laboratory abnormalities at screening\n\n          -  previous participation in a clinical trial with protease inhibitor and/or NS5A\n             inhibitor\n\n          -  HIV infection or other liver diseases\n\n          -  Positive Hepatitis B Surface Antigen\n\n          -  Liver cirrhosis\n\n          -  uncontrolled psychiatric disease\n\n          -  clinical evidence of chronic cardiac disease\n\n          -  history of malignancy of any organ system within 5 years"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "85 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "16", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 2, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01700179", 
            "org_study_id": "ACH102-005"
        }, 
        "intervention": [
            {
                "arm_group_label": "ACH-0143102 plus ribavirin", 
                "intervention_name": "ACH-0143102", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "ACH-0143102 plus ribavirin", 
                "intervention_name": "Ribavirin", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Antiviral Agents", 
                "Ribavirin"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "December 18, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Bakersfield", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "93301"
                    }, 
                    "name": "Dr. Franco Felizarta"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Marietta", 
                        "country": "United States", 
                        "state": "Georgia", 
                        "zip": "30060"
                    }, 
                    "name": "Dr. Aasim Sheikh"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nashville", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37211"
                    }, 
                    "name": "Dr. Robert Herring Jr"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77030"
                    }, 
                    "name": "Victor Ankoma-Sey"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Antonio", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "78215"
                    }, 
                    "name": "Dr. Eric Lawitz"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Fairfax", 
                        "country": "United States", 
                        "state": "Virginia", 
                        "zip": "22031"
                    }, 
                    "name": "Vinod Rustgi, MD"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lynchburg", 
                        "country": "United States", 
                        "state": "Virginia", 
                        "zip": "24501"
                    }, 
                    "name": "Robert Brennan"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Norfolk", 
                        "country": "United States", 
                        "state": "Virginia", 
                        "zip": "23502"
                    }, 
                    "name": "Michael Ryan, MD"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 1b, Open-label, Pilot Study to Evaluate the Safety, Tolerability and Antiviral Activity of Oral ACH-0143102 Administered in Combination With Ribavirin for 12 Weeks in Treatment Naive Subjects With Chronic Hepatitis C Virus Infection Genotype 1b.", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "September 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "To determine the incidence of a sustained virologic response at 12 weeks after the completion of dosing (SVR12) with ACH-0143102 plus ribavirin, reported as HCV RNA less than the limit of quantification (<LOQ) at that time point", 
            "measure": "SVR12", 
            "safety_issue": "No", 
            "time_frame": "12 weeks following last dose"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01700179"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Adverse events, ECG, Vital Signs, Physical Exams and clinical laboratory evaluations.", 
                "measure": "Safety and tolerability", 
                "safety_issue": "Yes", 
                "time_frame": "12 weeks"
            }, 
            {
                "description": "To determine the incidence of a complete early virologic response (cEVR), defined as HCV RNA reported as undetectable at Week 12, for combination therapy of ACH-0143102 plus RBV for 12 weeks in subjects with HVC infection genotype 1b.", 
                "measure": "To determine complete early virologic response(cEVR)", 
                "safety_issue": "Yes", 
                "time_frame": "12 weeks"
            }, 
            {
                "description": "To determine the incidence of a rapid virologic response (RVR), defined as HCV RNA<limit of quantification(LOQ) at Week 4, for combination therapy of ACH-0143102 plus RBV in subjects with HCV infection genotype 1b.", 
                "measure": "To determine the incidence of a rapid virologic response(RVR)", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "description": "To determine the incidence of an extended rapid virologic response(eRVR), defined as HCV RNA reported as undetectable at Weeks 4 and 12, for subjects treated with combination therapy of ACH-0143102 plus RBV  in subjects infected with hepatitis C virus genotype 1b.", 
                "measure": "To determine the incidence of an extended rapid virologic response(eRVR)", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "description": "To determine the incidence of a sustained virologic response at 4,8, and 24 weeks after the completion of dosing(SVR4,SVR12,and SVR24) with ACH-0143102 plus ribavirin, reported as HCV RNA less than the limit of quantification(<LOQ) at those time points.", 
                "measure": "To determine the incidence of a sustained virologic response", 
                "safety_issue": "No", 
                "time_frame": "24 weeks"
            }, 
            {
                "description": "AUC,Cmax,Tmax,virologic response.", 
                "measure": "To determine the pharmacokinetic and pharmacodynamic relationship of ACH-0143102 and RBV treatment and virologic response", 
                "safety_issue": "Yes", 
                "time_frame": "24 weeks"
            }
        ], 
        "source": "Achillion Pharmaceuticals", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Achillion Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}